Mutant p53 as a guardian of the cancer cell

被引:0
|
作者
Fiamma Mantovani
Licio Collavin
Giannino Del Sal
机构
[1] AREA Science Park,Laboratorio Nazionale CIB (LNCIB)
[2] Università degli Studi di Trieste,Dipartimento di Scienze della Vita
[3] IFOM—the FIRC Institute of Molecular Oncology,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Forty years of research have established that the p53 tumor suppressor provides a major barrier to neoplastic transformation and tumor progression by its unique ability to act as an extremely sensitive collector of stress inputs, and to coordinate a complex framework of diverse effector pathways and processes that protect cellular homeostasis and genome stability. Missense mutations in the TP53 gene are extremely widespread in human cancers and give rise to mutant p53 proteins that lose tumor suppressive activities, and some of which exert trans-dominant repression over the wild-type counterpart. Cancer cells acquire selective advantages by retaining mutant forms of the protein, which radically subvert the nature of the p53 pathway by promoting invasion, metastasis and chemoresistance. In this review, we consider available evidence suggesting that mutant p53 proteins can favor cancer cell survival and tumor progression by acting as homeostatic factors that sense and protect cancer cells from transformation-related stress stimuli, including DNA lesions, oxidative and proteotoxic stress, metabolic inbalance, interaction with the tumor microenvironment, and the immune system. These activities of mutant p53 may explain cancer cell addiction to this particular oncogene, and their study may disclose tumor vulnerabilities and synthetic lethalities that could be exploited for hitting tumors bearing missense TP53 mutations.
引用
收藏
页码:199 / 212
页数:13
相关论文
共 50 条
  • [41] p53: Guardian of the genome and policeman of the oncogenes
    Efeyan, Alejo
    Serrano, Manuel
    CELL CYCLE, 2007, 6 (09) : 1006 - 1010
  • [42] Mutant p53 exerts oncogenic functions by modulating cancer cell metabolism
    Zhou, Ge
    Myers, Jeffrey N.
    MOLECULAR & CELLULAR ONCOLOGY, 2014, 1 (03):
  • [43] Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53
    Amr Ghaleb
    Alisha Yallowitz
    Natalia Marchenko
    Communications Biology, 2
  • [44] Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53
    Ghaleb, Amr
    Yallowitz, Alisha
    Marchenko, Natalia
    COMMUNICATIONS BIOLOGY, 2019, 2 (01)
  • [45] p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines
    Janicek, MF
    Angioli, R
    Unal, AD
    Sevin, BU
    Madrigal, M
    Estape, R
    Averette, HE
    GYNECOLOGIC ONCOLOGY, 1997, 66 (01) : 94 - 102
  • [46] Targeting mutant p53 stabilization for cancer therapy
    Wang, Jiajian
    Liu, Wenjun
    Zhang, Lanqing
    Zhang, Jihong
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [47] Targeting mutant p53 for efficient cancer therapy
    Vladimir J. N. Bykov
    Sofi E. Eriksson
    Julie Bianchi
    Klas G. Wiman
    Nature Reviews Cancer, 2018, 18 : 89 - 102
  • [48] Mutant P53 Is a Key Determinant of Ovarian Cancer
    Mullany, Lisa K.
    Ren, Yi
    Marciano, David C.
    Wong, Kwong-Kwok
    King-Crane, Erin R.
    Katsonis, Panagiotis
    Liu, Zhilin
    Lichtarge, Olivier
    Richards, JoAnne S.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [49] Targeting mutant p53 for efficient cancer therapy
    Bykov, Vladimir J. N.
    Eriksson, Sofi E.
    Bianchi, Julie
    Wiman, Klas G.
    NATURE REVIEWS CANCER, 2018, 18 (02) : 89 - 102
  • [50] Targeting mutant p53 in cancer: the latest insights
    Di Agostino, Silvia
    Fontemaggi, Giulia
    Strano, Sabrina
    Blandino, Giovanni
    D'Orazi, Gabriella
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)